Immunotherapy for Renal Cell Carcinoma

Overview

Journal Clin Dev Immunol

Specialty Allergy & Immunology

Date 2011 Jan 22

PMID 21253521

Citations 31

Authors

Momoe Itsumi

Katsunori Tatsugami

Affiliations

Soon will be listed here.

Abstract

Immunotherapy plays a significant role in the management of renal cell carcinoma (RCC) patients with metastatic disease because RCC is highly resistant to both chemotherapy and radiation therapy. Many reports illustrate various approaches to the treatment of RCC, such as cytokine-, antigen- or dendritic cell- (DC-) based immunotherapy, and the safety and effectiveness of immunotherapy have been highlighted by multiple clinical trials. Although antitumor immune responses and clinically significant outcomes have been achieved in these trials, the response rate is still low, and very few patients show long-term clinical improvement. Recently, the importance of immune regulation by antigen-presenting cells (APC) and regulatory T cells (Treg cells) has also been discussed. The authors outline the principles of cell-mediated tumor immunotherapy and discuss clinical trials of immunotherapy for RCC.

Citing Articles

Emerging resistance losing response to immune check point inhibitors in renal cell carcinoma: two differing phenomena.

Roy A, George S Cancer Drug Resist. 2023; 6(3):642-655.

PMID: 37842239 PMC: 10571056. DOI: 10.20517/cdr.2023.47.

CDCA3 Predicts Poor Prognosis and Affects CD8 T Cell Infiltration in Renal Cell Carcinoma.

Bai Y, Liao S, Yin Z, You B, Lu D, Chen Y J Oncol. 2022; 2022:6343760.

PMID: 36213833 PMC: 9534638. DOI: 10.1155/2022/6343760.

Comprehensive Analysis of Somatic Mutation in Clear Cell Renal Cell Carcinoma.

Gong Z, Wu X, Guo Q, Du H, Zhang F, Kong Y Genes (Basel). 2022; 13(7).

PMID: 35886066 PMC: 9316380. DOI: 10.3390/genes13071282.

Is preoperative neutrophil-to-lymphocyte ratio a red flag which can predict high-risk pathological characteristics in renal cell carcinoma?.

Adapala R, Laxman Prabhu G, Sanman K, Yalla D, Shetty R, Venugopal P Urol Ann. 2021; 13(1):47-52.

PMID: 33897164 PMC: 8052900. DOI: 10.4103/UA.UA_34_19.

Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition.

Cervera-Carrascon V, Quixabeira D, Santos J, Havunen R, Zafar S, Hemminki O Oncoimmunology. 2020; 9(1):1761229.

PMID: 32923123 PMC: 7458667. DOI: 10.1080/2162402X.2020.1761229.

References

Dillman R, Barth N, VanderMolen L, Garfield D, de Leon C, OConnor A . Treatment of kidney cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma. Cancer Biother Radiopharm. 2001; 16(1):47-54. DOI: 10.1089/108497801750096023. View

Holtl L, Ramoner R, Zelle-Rieser C, Gander H, Putz T, Papesh C . Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide. Cancer Immunol Immunother. 2005; 54(7):663-70. PMC: 11032994. DOI: 10.1007/s00262-004-0629-2. View

Jonuleit H, Schmitt E, Schuler G, Knop J, Enk A . Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med. 2000; 192(9):1213-22. PMC: 2193357. DOI: 10.1084/jem.192.9.1213. View

van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B . A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991; 254(5038):1643-7. DOI: 10.1126/science.1840703. View

Bleumer I, Tiemessen D, Oosterwijk-Wakka J, Voller M, De Weijer K, Mulders P . Preliminary analysis of patients with progressive renal cell carcinoma vaccinated with CA9-peptide-pulsed mature dendritic cells. J Immunother. 2007; 30(1):116-22. DOI: 10.1097/01.cji.0000211318.22902.ec. View

Rini B, Zimmerman T, Stadler W, Gajewski T, Vogelzang N . Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol. 2002; 20(8):2017-24. DOI: 10.1200/JCO.2002.08.068. View

Kolb H, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G . Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990; 76(12):2462-5. View

Tatsugami K, Eto M, Naito S . Influence of immunotherapy with interferon-alpha on regulatory T cells in renal cell carcinoma patients. J Interferon Cytokine Res. 2009; 30(1):43-8. DOI: 10.1089/jir.2009.0014. View

Negrier S, Philip T, Stoter G, Fossa S, Janssen S, Iacone A . Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study. Eur J Cancer Clin Oncol. 1989; 25 Suppl 3:S21-8. View

10.

Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S . Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000; 343(11):750-8. DOI: 10.1056/NEJM200009143431101. View

11.

Barbuto J, Ensina L, Neves A, Bergami-Santos P, Leite K, Marques R . Dendritic cell-tumor cell hybrid vaccination for metastatic cancer. Cancer Immunol Immunother. 2004; 53(12):1111-8. PMC: 11032787. DOI: 10.1007/s00262-004-0551-7. View

12.

Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, CIVIDALLI G . Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998; 91(3):756-63. View

13.

Tatsugami K, Eto M, Harano M, Nagafuji K, Omoto K, Katano M . Dendritic-cell therapy after non-myeloablative stem-cell transplantation for renal-cell carcinoma. Lancet Oncol. 2004; 5(12):750-2. DOI: 10.1016/S1470-2045(04)01652-3. View

14.

Jonasch E, Wood C, Tamboli P, Pagliaro L, Tu S, Kim J . Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. Br J Cancer. 2008; 98(8):1336-41. PMC: 2361701. DOI: 10.1038/sj.bjc.6604266. View

15.

van Poppel H, Joniau S, Van Gool S . Vaccine therapy in patients with renal cell carcinoma. Eur Urol. 2009; 55(6):1333-42. DOI: 10.1016/j.eururo.2009.01.043. View

16.

Shimizu J, Yamazaki S, Sakaguchi S . Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol. 1999; 163(10):5211-8. View

17.

Padovan E, Spagnoli G, Ferrantini M, Heberer M . IFN-alpha2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector T cells. J Leukoc Biol. 2002; 71(4):669-76. View

18.

Antonia S, Seigne J, Diaz J, Muro-Cacho C, Extermann M, Farmelo M . Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J Urol. 2002; 167(5):1995-2000. View

19.

Wittig B, Marten A, Dorbic T, Weineck S, Min H, Niemitz S . Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical phase I/II trial. Hum Gene Ther. 2001; 12(3):267-78. DOI: 10.1089/10430340150218404. View

20.

Arroyo J, Gabilondo F, Llorente L, Meraz-Rios M, Sanchez-Torres C . Immune response induced in vitro by CD16- and CD16+ monocyte-derived dendritic cells in patients with metastatic renal cell carcinoma treated with dendritic cell vaccines. J Clin Immunol. 2004; 24(1):86-96. DOI: 10.1023/B:JOCI.0000018067.71622.fb. View